CryoLife is one of the world’s contemporary medical device companies providing preserved human cardiac and vascular tissues, surgical adhesives and sealants, cardiac lasers and implantable end-stage renal disease access grafts for the repair of complex cardiac and vascular reconstruction surgeries. 
CryoLife using its proprietary SynerGraft technology processes the CryoValve SG pulmonary heart valve and CryoPatch SG pulmonary cardiac patch. CryoLife’s CardioGenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as Transmyocardial Revascularization (TMR). CryoLife markets the HeRO Graft, which provides vascular access for hemodialysis patients. CryoLife distributes PerClot, an absorbable powdered hemostat, in international markets. CryoLife’s BioFoam Surgical Matrix is CE marked in the European Community for use as an adjunct to hemostasis.

Show more
Type
Public
HQ
Kennesaw, US
Founded
1984
Size (employees)
665 (est)
CryoLife was founded in 1984 and is headquartered in Kennesaw, US
Report incorrect company information

Key People/Management at CryoLife

Thomas F. Ackerman

Thomas F. Ackerman

Member of the Board

CryoLife Office Locations

CryoLife has offices in Paris, Singapore, Freiburg im Breisgau, Kennesaw and in 1 other location
Kennesaw, US (HQ)
1655 Roberts Blvd
Paris, FR
52 Rue de la Victoire
Freiburg im Breisgau, DE
19 Engelbergerstraße
Singapore, SG
1 Marina Blvd
Guildford, GB
Old Portsmouth Rd
Show all (5)
Report incorrect company information

CryoLife Financials and Metrics

CryoLife Financials

CryoLife's revenue was reported to be $189.70 m in FY, 2017
USD

Revenue (Q1, 2018)

61.9 m

Net income (Q1, 2018)

(3.9 m)

EBIT (Q1, 2018)

(3.5 m)

Market capitalization (14-Jun-2018)

1.1 b

Closing share price (14-Jun-2018)

29.1

Cash (31-Mar-2018)

26.6 m

EV

1.3 b
CryoLife's current market capitalization is $1.1 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

140.8 m144.6 m145.9 m180.4 m189.7 m

Revenue growth, %

3%1%24%

R&D expense

13.4 m19.5 m

Operating expense total

13.4 m120.7 m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

43 m47.1 b45.3 m45.1 m47.8 m44 m61.9 m

R&D expense

2.6 m3.3 b3.7 m4.1 m4.7 m4.3 m5.4 m

Operating expense total

28.9 m25.7 b24.3 m27 m28.1 m29 m42.7 m

EBIT

6.7 m4.6 b5.5 m2.5 m4.8 m829 k(3.5 m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

37.6 m33.4 m37.6 m56.6 m40 m

Accounts Receivable

136.7 m

Inventories

9.8 m12.7 m14.6 m26.3 m46.7 m

Current Assets

106.3 m106 m109.7 m147.2 m179.3 m
Quarterly
USDQ1, 2014Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

32.8 m44.8 m46.9 m54.1 m58.9 m52.5 m54.2 m26.6 m

Inventories

11.5 m25.3 m25.4 m25.5 m25.8 m26.5 m27.8 m44.6 m

Current Assets

105.9 m129.2 m135.8 m142.1 m149.2 m152.2 m155.6 m166.8 m

PP&E

12 m16.5 m16.4 m17.2 m20.2 m20.7 m20.6 m34.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

16.2 m7.3 m4 b10.8 m3.7 m

Depreciation and Amortization

5.8 m6 m5.9 b8.4 m9.7 m

Inventories

Accounts Payable

Quarterly
USDQ1, 2014Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

1.1 m2.5 m4.9 m7.9 m2.2 m5.4 m6.7 m(3.9 m)

Depreciation and Amortization

1.5 m1.9 m4.1 m6.2 m2.2 m4.4 m6.7 m4.4 m

Cash From Investing Activities

(1.7 m)(67.2 m)(69.2 m)(71.1 m)(1.2 m)(3.6 m)(4.6 m)(2.1 m)

Dividends Paid

(772 k)(850 k)(1.7 m)(2.6 m)
USDY, 2018

EV/EBIT

-360 x

Financial Leverage

2.1 x
Show all financial metrics
Report incorrect company information

CryoLife Online and Social Media Presence

Embed Graph
Report incorrect company information

CryoLife News and Updates

Marna Borgstrom Joins CryoLife Board of Directors

ATLANTA, June 19, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, today announced the appointment of Marna Borgstrom to its Board of Directors effective immediately. Pat Mackin, Chairman, President, and Chief...

CryoLife Announces Peer Review Publication of On-X® Aortic Heart Valve PROACT Study

ATLANTA, June 11, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, today announces the publication of our clinical study entitled "Anticoagulation and Antiplatelet Strategies After On-X Mechanical Aortic Valve...
Report incorrect company information